Clinical impact of PD-L1 assay discordance across antibody clones in advanced gastric cancer treated with first-line immunotherapy (KINGCA Week 2026) - Oct 11, 2026 - Abstract #GS-4; Pres time: Sep 18, 2026; 02:00 PM - 02:20 PM; Location: Room C; "Survival analyses focused on 295 patients treated with first-line nivolumab plus chemotherapy... PD-L1 antibody clones are not clinically interchangeable in AGC. Discordance among assays is not merely an analytical phenomenon but is associated with poorer outcomes after first-line ICI plus chemotherapy. Recognizing clone-dependent discordance may refine interpretation of PD-L1 results and improve biomarker-based treatment stratification."
Clinical • Discordant • IO biomarker • Metastases • Gastric Cancer • Oncology • Solid Tumor
|